Showing results (621-630 of 1,454) with videos related to

Sort By:
Pageof 146
Sangre|April 1, 1990
[Idiopathic myelofibrosis: clinical course, survival, and causes of death in a series of 60 patients]A López-Guillermo, F Cervantes, M Rovira, et al.
The Malaysian Journal of Medical Sciences : MJMS|May 17, 2012
The vanishing veins: difficult venous access in a patient requiring translumbar, transhepatic, and transcollateral central catheter insertionYazmin Yaacob, Rozman Zakaria, Zahiah Mohammad, et al.
Archives of Toxicology. Supplement. = Archiv Fur Toxikologie. Supplement|January 1, 1992
Decreased hepatic phosphoenolpyruvate carboxykinase gene expression after 2,3,7,8-tetrachlorodibenzo-p-dioxin treatment: implications for the acute toxicity of chlorinated dibenzo-p-dioxins in the ratB U Stahl, D G Beer, L W Weber, et al.
Sangre|October 1, 1993
[Multiple myeloma after monoclonal gammopathy of uncertain significance. Study of 10 patients]C Salgado, J Bladé, A López-Guillermo, et al.
Cancer|February 1, 1983
VP-16 plus cyclophosphamide in the treatment of advanced lung cancerJ Estape, A Milla, A Agusti, et al.
Medicina Cutanea Ibero-Latino-Americana|January 1, 1983
[Cutaneous myelofibrosis]T Estrach, J Palou, E Martín, et al.
Medicina Clinica|June 6, 1992
[Behçet's disease with an onset prior to the appearance of chronic myeloid leukemia]D Tassies, F Cervantes, E Feliu, et al.
Toxicology and Applied Pharmacology|July 1, 1994
A pharmacodynamically responsive model of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) transfer between liver and fat at low and high dosesW L Roth, S Ernst, L W Weber, et al.
Frontiers in Pharmacology|July 18, 2017
Evaluation of Selected CYP51A1 Polymorphisms in View of Interactions with Substrate and Redox PartnerTadeja Režen, Iza Ogris, Marko Sever, et al.
Medicina Clinica|March 9, 1991
[Tuberculosis in chronic myeloproliferative syndromes: its incidence and principle characteristics in a series of 562 patients]D Tassies, F Cervantes, J M Nicolás, et al.
Pageof 146